Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Yong-Pyo LeeHyun Ae JungMin-Sang LeeJung Won ChoiDoo-Sik KongHo Jun SeolDo-Hyun NamJung-Il LeeSe-Hoon LeePublished in: Journal of neuro-oncology (2022)
Bevacizumab plus irinotecan was well-tolerated and moderately effective in patients with high-grade gliomas. The addition of GKS prior to bevacizumab plus irinotecan led to a significant OS benefit with a manageable safety profile. GKS prior to bevacizumab plus irinotecan can therefore be considered a potential treatment option for these patients.
Keyphrases
- high grade
- metastatic colorectal cancer
- low grade
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- radiation therapy
- prognostic factors
- photodynamic therapy
- combination therapy
- patient reported outcomes
- rectal cancer
- risk assessment
- drug delivery
- brain metastases